Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism

Brain

Volumn 127, Issue 6, 2004, Pages 1332-1342

  Scherfler, Christoph ^a   Khan, Naheed L ^b   Pavese, Nicola ^a   Eunson, Louise ^b   Graham, Elizabeth ^b   Lees, Andrew J ^c   Quinn, Niall P ^c   Wood, Nicholas W ^b   Brooks, David J ^a   Piccini, Paola P ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

11C raclopride; 18F dopa; parkin gene; PET; SPM

Indexed keywords

CARBON 11; DOPA; FLUORINE 18; PARKIN; RACLOPRIDE;

ADULT; AGED; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN MAPPING; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DOWNSTREAM PROCESSING; DRUG UPTAKE; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMAGE ANALYSIS; MALE; MESENCEPHALON; NEUROIMAGING; ONSET AGE; ORBITAL CORTEX; PARIETAL LOBE; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC INHIBITION; PRESYNAPTIC NERVE; PRIORITY JOURNAL; TEMPORAL CORTEX;

ADULT; AGE OF ONSET; AGED; CEREBRAL CORTEX; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED; UBIQUITIN-PROTEIN LIGASES;

EID: 2942534518     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh150     Document Type: Article

References (59)

1. Abbas N, Lucking CB, Ricard S, Durr A, Bonifati V, De Michele G, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet 1999; 8: 567-74.
2. Ahlskog JE, Richelson E, Nelson A, Kelly PJ, Okazaki H, Tyce GM, et al. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients. Ann Neurol 1991; 30: 185-91.
3. 11C-raclopride. Arch Neurol 1993; 50: 474-80.
4. 11C]raclopride. Mov Disord 1997; 12: 33-8.
5. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-55.
6. 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31: 184-92.
7. 18F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations. Neurology 2000; 55: 877-9.
8. Doudet DJ, Holden JE, Jivan S, McGeer E, Wyatt RJ. In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism. Synapse 2000; 38: 105-13.
9. 18F]-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993; 13: 881-8.
10. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park (NJ): MacMillan Health Care Information; 1987. p. 153-63.
11. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231: 258-61.
12. Farde L, Gustavsson JP, Jonsson E. D2 dopamine receptors and personality traits. Nature 1997; 385-590.
13. 18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 1987; 48: 1077-82.
14. Friston, KJ, Ashburner J, Frith CD, Poline JB, Heather JD, Frackowiak RS. Spatial registration and normalization of images. Hum Brain Mapp 1995; 3: 165-89.
15. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983; 305: 137-8.
16. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
17. Griffiths PD, Perry RH, Crossman AR. A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neurosci Lett 1994; 169: 68-72.
18. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279-87.
19. Guttman M, Seeman P. L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum. J Neural Transm 1985; 64: 93-103.
20. 125I]epidepride. Synapse 1996; 23: 115-23.
21. Halldin C, Farde L, Hogberg T, Mohell H, Hall H, Suhara T, et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 1995; 36: 1275-81.
22. Hattori N, Kitada T, Matsumine H, Asakawa S, Yamamura Y, Yoshino H, et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 1998; 44: 935-41.
23. Hayashi S, Wakabayashi K, Ishikawa A, Nagai H, Saito H, Maruyama M, et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 2000; 15: 884-8.
24. Hilker R, Klein C, Ghaemi M, Kis B, Strotmann T, Ozelius LJ, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001; 49: 367-76.
25. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
26. Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 1996; 47: 160-6.
27. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/ SPECT and fluorine-18-DOPA/PET. J Nucl Med 1996; 37: 1760-5.
28. Joyce JN, Goldsmith SG, Gurevich EV. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. J Psychiatr Res 1997; 31: 197-217.
29. Joyce JN, Myers AJ, Gurevich E. Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease. Brain Res 1998; 784: 7-17.
30. Kaasinen V, Nagren K, Hietala J, Oikonen V, Vilkman H, Farde L, et al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 2000; 54: 1482-7.
31. 125I]epidepride. Brain Res 1993; 609: 237-43.
32. 18F]dopa PET and clinical study. Brain 2002a; 125: 2248-56.
33. 18F]-dopa PET study. Ann Neurol 2002b; 52: 849-53.
34. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-8.
35. Laasko A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvalahti E, et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry 2002; 52: 759-63.
36. Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH. Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease. Hum Genet 1998; 103: 424-7.
37. 3H]raclopride. Proc Natl Acad Sci USA 1989; 86: 6412-6.
38. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 2000; 342: 1560-7.
39. Martin WR, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989; 26: 535-42.
40. Maruyama M, Ikeuchi T, Saito M, Ishikawa A, Yuasa T, Tanaka H, et al. Novel mutations, pseudo-dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism. Ann Neurol 2000; 48: 245-50.
41. Matsumine H, Saito M, Shimoda-Matsubayashi S, Tanaka H, Ishikawa A, Nakagawa-Hattori Y, et al. Localization of a gene for an autosomal recessive form of juvenile parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997; 60: 588-96.
42. Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, Miyake T, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998; 51: 890-2.
43. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
44. Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003; 126: 1127-35.
45. Piccini P, Pavese N, Brooks DJ. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 2003; 53: 647-53.
46. Pohjalainen T, Rinne JO, Nagren K, Syvalathi E, Hietala J. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 1998; 115: 768-73.
47. Portman AT, Giladi N, Leenders KL, Maguire P, Veenma-van der Duin L, Swart J, et al. The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Neurology 2001; 56: 1759-62.
48. Pramstaller PP, Kunig G, Leenders K, Kann M, Hedrich K, Vieregge P, et al. Parkin mutations in a patient with hemiparkinsonism-hemiatrophy: a clinical-genetic and PET study. Neurology 2002; 58: 808-10.
49. 18F]dopa-PET study. Brain 1999; 122: 1637-50.
50. Ribeyre JM, Lesieur P, Varoquaux O, Dollfus S, Pays M, Petit M. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 1994; 36: 230-6.
51. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990; 28: 799-804.
52. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001; 293: 263-9.
53. Spinks TJ, Jones T, Bloomfield PM, Bailey DL, Miller M, Hogg D, et al. Physical characteristics of the ECAT EXACT3D positron tomograph. Phys Med Biol 2000; 45: 2601-18.
54. Takahashi H, Ohama E, Suzuki S, Horikawa Y, Ishikawa A, Morita T, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 1994; 44: 437-41.
55. Thobois S, Ribeiro MJ, Lohmann E, Durr A, Pollak P, Rascol O, et al. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F18 positron emission tomography study. Arch Neurol 2003; 60: 713-8.
56. Tison F, Normand E, Jaber M, Aubert I, Bloch B. Aromatic L-amino-acid decarboxylase (DOPA decarboxylase) gene expression in dopaminergic and serotoninergic cells of the rat brainstem. Neurosci Lett 1991; 127: 203-6.
57. VandeWarrenburg BP, Lammens M, Lucking CB, Denefle P, Wesseling P, Booji J, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001; 56: 555-7.
58. Whone AL, Moore RY, Piccini P, Brooks DJ. Plasticity of the nigrapallidal pathway in Parkinson's disease. Ann Neurol 2003; 53: 206-13.
59. Yamamura Y, Sobue I, Ando K, Iida M, Yanagi T. Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. Neurology 1973; 23: 239-44.